Kubota Pharmaceutical Holdings Co., Ltd.

Tokyo Stock Exchange 4596.T

Kubota Pharmaceutical Holdings Co., Ltd. Revenue for the year ending December 31, 2023: USD 282.68 K

Kubota Pharmaceutical Holdings Co., Ltd. Revenue is USD 282.68 K for the year ending December 31, 2023, a 349.21% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Kubota Pharmaceutical Holdings Co., Ltd. Revenue for the year ending December 31, 2022 was USD 62.93 K, a 0.00% change year over year.
  • Kubota Pharmaceutical Holdings Co., Ltd. Revenue for the year ending December 31, 2021 was USD 0.00, a -100.00% change year over year.
  • Kubota Pharmaceutical Holdings Co., Ltd. Revenue for the year ending December 31, 2020 was USD 365.66 K, a 0.00% change year over year.
  • Kubota Pharmaceutical Holdings Co., Ltd. Revenue for the year ending December 31, 2019 was USD 0.00.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Tokyo Stock Exchange: 4596.T

Kubota Pharmaceutical Holdings Co., Ltd.

CEO Dr. Ryo Kubota M.D., Ph.D.
IPO Date Dec. 6, 2016
Location Japan
Headquarters 3-7-1 Kasumigaseki
Employees 12
Sector Health Care
Industries
Pharmaceuticals
Description

Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.

StockViz Staff

January 15, 2025

Any question? Send us an email